/
Oncology
Biliary Tract Cancer
90
Pipeline Programs↗
118
Active Trials↗
57
Companies Involved↗
Biliary Tract Cancer is a moderately active landscape with 90 programs across 57 companies. The most active players are AstraZeneca, Sichuan Baili Pharmaceutical Co., Ltd., Qilu Pharmaceutical Co., Ltd.. 23 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical7
Phase 12
Phase 258
Phase 323
Approved
No programs
Analysis
Modality Breakdown
69%
Small molecule
57 of 83 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 83 classified programs, each share of the total. Modality classified for 94% of 90 pipeline programs.
Analysis
Trial Status
265
clinical trials
Completed84 · 32%
Recruiting59 · 22%
Unknown status41 · 15%
Not yet recruiting32 · 12%
Active, not recruiting27 · 10%
Terminated12 · 5%
Other10 · 4%
Clinical Trials
Trial Activity
265 trials
A Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer
Recruiting·—·Approved·NCT07619235·32 enrolled
A Prospective, Single-Arm, Exploratory Clinical Study of Liposomal Irinotecan (II) Plus 5-Fluorouracil/Leucovorin and Sintilimab With Sequential Stereotactic Body Radiation Therapy as First-Line Treatment for Locally Advanced Biliary Tract Cancer
Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT07797816·31 enrolled
Safety and Effectiveness of Sequential Cryoablation With Rilafup α and Chemotherapy as First-line Treatment for Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: a Multicenter, Prospective, Single-arm, Phase II Clinical Study
Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07726446·30 enrolled
Page 1 of 18
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)